|
|
||
|
|
United States Patent: 5,942,245 Inventors: Katinger; Hermann (Wien, AT); Vorauer-Uhl; Karola (Wien, AT); Furnschlief; Eckhard (Wien, AT)Assignee: Polymun Scientific Immunbiologische Forschung GmbH (AT) Appl. No.: 836185Filed: May 5, 1997 Superoxide dismutase (SOD), preferably rhSOD, is used in liposomes, optionally mixed with hyaluronic acid and/or at least one physiologically acceptable carrier, and other optional additives, to prepare a pharmaceutical composition useful against increased concentrations of superoxide radicals and/or the damage caused thereby. These compositions can be administered topically, orally and/or parenterally to prevent and/or heal burns, skin lesions due to radiation, inflammations, rheumatic and arthritic diseases, bronchitis, ARDS, emphysema, allergic oedemas and other inflammatory process, possibly trigged by microbial infections. They may also be used in the cosmetic treatment of furuncles, acne and the like. They may also be used to improve the preservability of organic, preferably biogenic, materials, in particular organ transplants and liquids with organic components, as well as foodstuffs. Summary of the Invention The primary object of the present invention is to
provide pharmaceutical compositions for transporting SOD,
preferably rhSOD enclosed in protective liposomes, in a gentle,
effective manner and with better bioavailability, to those parts
of the body which are to be treated. In spite of a continuing
general prejudice on the part of those skilled in the art, the
inventors have been able in particular to use liposomally packaged
SOD successfully for burns and scalds and for radiation damage,
caused, for example, by UV radiation or ionizing radiation, in
particular by external application. In the case of exposure to
radiation, prophylactic use, for example together with a
radiation-filtering or radiation-absorbing screening agent, is
also possible in addition to therapeutic use. Claim 1 of 20 Claims 1. A pharmaceutical composition comprising a low-fat or fat free carrier together with recombinant human Cu, Zn--SOD (rhSOD) in unilamellar liposomes having an average diameter of 200 nm or less, wherein the rhSOD is present in a concentration of 0.01 to 5% by weight based on the composition, for topical administration to a human body or part thereof. ____________________________________________
|
|
|